Market Cap | 4.97M | P/E | - | EPS this Y | 16.70% | Ern Qtrly Grth | - |
Income | -5.34M | Forward P/E | -1.03 | EPS next Y | - | 50D Avg Chg | 32.00% |
Sales | 1.15M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 21.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -50.00% |
Recommedations | - | Quick Ratio | 0.41 | Shares Outstanding | 121.27M | 52W Low Chg | 86.00% |
Insider Own | 0.06% | ROA | -215.78% | Shares Float | 106.83M | Beta | 1.15 |
Inst Own | 11.84% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.04 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 203,546 | Target Price | 0.15 |
Oper. Margin | -401.26% | Earnings Date | Jun 21 | Volume | 19,784 | Change | -2.38% |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.